Overview

This trial is active, not recruiting.

Conditions essential tremor, multiple system atrophy, corticobasal degeneration, supranuclear palsy, progressive
Sponsor University of Colorado, Denver
Start date November 2013
End date December 2014
Trial size 18 participants
Trial identifier NCT02132052, 11-0952

Summary

Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective

Primary Outcomes

Measure
Focal oscillatory activity
time frame: May 2014

Secondary Outcomes

Measure
Spectral coherence:
time frame: May 2014
Spectral Granger analysis:
time frame: May 2014
Reactivity:
time frame: May 2014
Complex network analysis:
time frame: May 2014

Eligibility Criteria

Male or female participants at least 40 years old.

Inclusion Criteria: - All subjects will be age 40 or older, - Be on stable medications for at least 30 days - Montreal Cognitive Assessment (MOCA) of 26 or higher and scores within 1.5 standard deviations of age-matched norms for all neuropsychological tests - PD will be defined using United Kingdom (UK) Brain Bank Criteria. - PDD will be defined using the Movement Disorder Task Force 2007 criteria and supported by scores less than 1.5 standard deviations of age-matched norms in at least two domains. - Probable AD will be defined using the National Institute on Aging-Alzheimer Association 2011 guidelines. - PD with MCI will be defined by history, MOCA of 21 or higher, at least one score less than 1.5 standard deviations of age-matched norms, and cannot meet diagnostic criteria for PDD. - Essential tremor and Parkinson plus syndromes (multiple systems atrophy, corticobasal degeneration, progressive supranuclear palsy) will be defined using previously published research criteria.19-22 Exclusion Criteria - Features suggestive of other causes of parkinsonism/Parkinson-plus syndromes; - Features suggestive of other causes of dementia, including moderate to severe cerebrovascular disease by history or imaging or history of major head trauma; - History of deep brain stimulation, ablation surgery, or other brain surgery; - Evidence for depression based on the Hospital Anxiety Depression Scale (score > 11).

Additional Information

Official title Defining Cognitive and Motor Phenotypes of Parkinson's Disease (PD) With Magnetoencephalography
Description Specific Aim 1: Determine which features of resting Magnetoencephalography (MEG) brain activity most sensitively discriminate between PD with normal cognition, PD with mild cognitive impairment (MCI), and PD dementia (PDD). Investigators predict that frontal network slowing and connectivity will discriminate between normal cognition and MCI while visuospatial network involvement will distinguish the PDD group. Specific Aim 2: Determine which features of resting MEG brain activity most sensitively discriminate PDD from Alzheimer's Disease. Investigators predict that PDD will be distinguished from Alzheimer's (AD) on the basis of increased network connectivity, particularly in frontal and visuospatial networks. Specific Aim 3 Investigate how resting state MEG activity correlates with task related brain activity. Investigators predict that resting state slowing will be associated with decreased task related brain activity. Specific Aim 4: Determine which features of resting MEG brain activity most sensitively discriminate between motor subtypes of PD and also other relevant clinical populations (essential tremor and Parkinson plus syndromes). Investigators predict that frontal and parietal slowing and connectivity will discriminate PD from related conditions and that patterns of motor cortex connectivity and activity will differentiate among PD motor phenotypes.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by University of Colorado, Denver.